An Accurate Prostate Cancer Prognosticator Using a Seven-Gene Signature Plus Gleason Score and Taking Cell Type Heterogeneity into Account

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Chen, Xin ^a   Xu, Shizhong ^b   McClelland, Michael ^a,c   Rahmatpanah, Farah ^a   Sawyers, Anne ^a   Jia, Zhenyu ^a   Mercola, Dan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Vaccine Research Institute of San Diego   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ACCURACY; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CELL HETEROGENEITY; CELL TYPE; CLASSIFIER; CLUSTER ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE EXPRESSION; GENETIC IDENTIFICATION; GENETIC SELECTION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREDICTION; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SEVEN GENE CLASSIFIER; STROMA CELL; TUMOR CELL;

CLUSTER ANALYSIS; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENES, NEOPLASM; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGAN SPECIFICITY; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84866988976     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045178     Document Type: Article

References (26)

1. ACS (2011) American Cancer Society: Cancer Facts & Figures 2011 [online].
2. Gerber GS, Thisted RA, Scardino PT, Frohmuller HGW, Schroeder FH, et al. (1996) Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 276: 615-619.
3. Walsh PC, (2000) Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J Urol 163: 1802-1807.
4. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, et al. (2005) Risk of prostate cancerâ€"specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 294: 433-439.
5. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597.
6. Kattan MW, Eastham JA, Stapleton AMF, Wheeler TM, Scardino PT, (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Nati Cancer Inst 90: 766-771.
7. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, et al. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969-974.
8. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, et al. (2005) The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173: 1938-1942.
9. Barwick BG, Abramovitz M, Kodani M, Moreno CS, Nam R, et al. (2010) Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts. BJC 102: 570-576.
10. Bibikova M, Chudin E, Arsanjani A, Zhou L, Garcia EW, et al. (2007) Expression signatures that correlated with Gleason score and relapse in prostate cancer. Genomics 89: 666-672.
11. Bickers B, Aukim-Hastie C, (2009) New molecular biomarkers for the prognosis and management of prostate cancer-the post PSA era. Anticancer Res 29: 3289-3298.
12. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
13. Smyth GK, (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl in Genet and Mol Biol 3: A3.
14. Jia Z, Wang Y, Sawyers A, Yao H, Rahmatpanah F, et al. (2011) Diagnosis of prostate cancer using differentially expressed genes in stroma. Cancer Res 71: 2476-2487.
15. Stuart RO, Wachsman W, Berry CC, Wang-Rodriguez J, Wasserman L, et al. (2004) In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. Proc Natl Acad Sci U S A 101: 615-620.
16. Wang Y, Xia XQ, Jia Z, Sawyers A, Yao H, et al. (2010) In silico Estimates of Tissue Components in Surgical Samples Based on Expression Profiling Data. Cancer Res 70: 6448-6455.
17. Chen X, Xu S, Wang Y, McClelland M, Jia Z, et al. (2011) Identification of Biomarkers for Prostate Cancer Prognosis Using a Novel Two-Step Cluster Analysis. Lecture Notes in Bioinformatics 7036: 63-74.
18. Sun Y, Goodison S, (2009) Optimizing molecular signatures for predicting prostate cancer recurrence. Prostate 69: 1119-1127.
19. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, et al. (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8: 393-406.
20. Dempster AP, Laird NM, Rubin DB, (1977) Maximum likelihood from incomplete data via the EM algorithm. J Royal Stat Soc 39: 1-38.
21. Schwarz G, (1978) Estimating the dimension of a model. Ann Stat 6: 461-464.
22. Kass RE, Raftery AE, (1995) Bayes factors. J Am Stat Ass 90: 773-795.
23. Guo Y, Hastie T, Tibshirani R, (2007) Regularized linear discriminant analysis and its application in microarrays. Biostatistics 8: 86-100.
24. de Sousa Abreu R, Penalva LO, Marcotte EM, Vogel C, (2009) Global signatures of protein and mRNA expression levels. Mol BioSyst 5: 1512-1526.
25. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL, (2004) Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113: 913-923.
26. Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, et al. (2006) Defining aggressive prostate cancer using a 12-gene model. Neoplasia 8: 59-68.